anaesthesia was introduced as a safer alternative, and the initial description 12 stated that 'complications of retrobulbar anesthesiayare greatly minimized in peribulbar anesthesiay'. Unfortunately, this has not proved to be the case, as the two techniques have similar incidences of globe perforation and brain-stem depression. 11, 13 Sub-Tenon anaesthesia has now been associated with globe perforation, 14 and many glaucoma surgeons are concerned that the technique may jeopardise the outcome of future filtering surgery. Topical anaesthesia does avoid the risks of the needle, but some surgeons are unhappy to operate on a potentially mobile eye, and the technique does not block the oculo-cardiac and other reflexes.
So, how can we audit the safety of LA for cataract surgery? Since serious problems are rare, a large sample size is required. This means a study on a national scale, lasting many months. This was last done in the UK in 1996, when the Royal College of Anaesthetists and the Royal College of Ophthalmologists sponsored the National Survey of Local Anaesthesia for Ocular Surgery. 8, 13 This observational study looked at safety aspects of around 65 000 LAs which were given over a 3-month period. Sight-and life-threatening complications were reported in around 0.05% of retrobulbar and peribulbar injections, 13 although the true figure is probably higher 11 due to underreporting. There were too few cases performed using sub-Tenon, subconjunctival, topical or topical-intracameral anaesthesia to assess their safety with any degree of certainty. 13 The safety of these 'newer' LA techniques has not been assessed in any large clinical study. Published series, comprising a few thousand cases each, appear to confirm low complication rates, but case series produced by centres with an interest in LA safety should always be interpreted with caution. For example, the safety profile shown in the initial published series of 16 224 peribulbar LAs 15 has not been replicated in the 'real world'. 11 As a result of the recent increase in usage of topical and sub-Tenon LA, it is time for this subject to be revisited.
Last autumn, a second national survey of LA safety began. This new survey is carried out by the same investigators as the 1996 survey, with broadly similar study aims and design. This time, the study takes place through the British Ophthalmic Surveillance Unit (BOSU), which was set up to facilitate case ascertainment for studies of rare ophthalmic conditions. BOSU mails a return-addressed postcard to all ophthalmologists of consultant and associate specialist grade in the UK and Eire, enquiring whether they have seen any cases of a limited number of specified conditions in the preceding month. For this study, ophthalmologists are asked to provide details of any case in which a potentially life-or sight-threatening complication occurred after LA was given for cataract surgery. Each case so identified will engender a brief questionnaire, asking what LA technique was used, what happened and what the outcome was. Case ascertainment through BOSU will continue for 1 year. At the midpoint, a questionnaire will be sent to the above ophthalmologists, in order to assess current usage of LA and of the various LA techniques. This study will, therefore, look at the safety of tens of thousands of sub-Tenon, topical and injection LAs, and should be able to give a reasonable idea of their safety in routine clinical practice.
From our knowledge of ocular anatomy and physiology, we would expect that sub-Tenon's or topical LA would be safer than retrobulbar or peribulbar injections. As indicated above, there has been no large study to confirm or refute this presumption. If the current trend towards using these techniques is to continue, it is important to be certain that these LA techniques are at least as safe as their predecessors. The BOSU study will go some way towards answering this question, and the results will be of interest to ophthalmic anaesthetists and cataract surgeons everywhere.
